122 related articles for article (PubMed ID: 31785493)
21. Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation.
Aguilar E; García-Díaz AM; Sánchez Muñoz-Torrero JF; Alvarez LR; Piedecausa M; Arnedo G; Monreal M;
Thromb Res; 2012 Sep; 130(3):390-5. PubMed ID: 22658293
[TBL] [Abstract][Full Text] [Related]
22. Proton Pump Inhibitor Use and the Risk of Cardiovascular Complications and Death in Older Adults with Diabetes: A Population-Based Cohort Study.
Foresta A; Fernandez LO; Torrigiani G; Schena S; Roncaglioni MC; Nobili A; Tettamanti M; Franchi C; Fortino I; Succurro E; Sesti G; Baviera M
Drugs Aging; 2024 Mar; 41(3):239-249. PubMed ID: 38367169
[TBL] [Abstract][Full Text] [Related]
23. Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease.
Volis I; Saliba W; Jaffe R; Eitan A; Zafrir B
Am J Cardiol; 2020 Aug; 128():28-34. PubMed ID: 32650921
[TBL] [Abstract][Full Text] [Related]
24. Anemia and Outcome in Outpatients With Peripheral Artery Disease.
Perez P; Esteban C; Caballero PE; Muñoz-Torrero JF; Soria MT; Aguilar E; Rodríguez LR; Sahuquillo JC; Díaz AM; Monreal M;
Angiology; 2016 May; 67(5):484-9. PubMed ID: 26271128
[TBL] [Abstract][Full Text] [Related]
25. Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular, or peripheral artery disease.
Alvarez LR; Balibrea JM; Suriñach JM; Coll R; Pascual MT; Toril J; López-Jiménez L; Monreal M;
Eur J Prev Cardiol; 2013 Jun; 20(3):486-95. PubMed ID: 21968571
[TBL] [Abstract][Full Text] [Related]
26. Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes.
Geng T; Chen JX; Zhou YF; Lu Q; Wan Z; Liu L; Pan A; Liu G
J Clin Endocrinol Metab; 2023 May; 108(6):e216-e222. PubMed ID: 36573284
[TBL] [Abstract][Full Text] [Related]
27. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L;
Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200
[TBL] [Abstract][Full Text] [Related]
28. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Bonaca MP; Bhatt DL; Storey RF; Steg PG; Cohen M; Kuder J; Goodrich E; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Dalby A; Špinar J; Aylward P; Corbalán R; Abola MTB; Jensen EC; Held P; Braunwald E; Sabatine MS
J Am Coll Cardiol; 2016 Jun; 67(23):2719-2728. PubMed ID: 27046162
[TBL] [Abstract][Full Text] [Related]
29. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism.
Madridano O; del Toro J; Lorenzo A; Martín M; Gómez Cerezo J; Hernández L; Prandoni P; Monreal M;
J Vasc Surg Venous Lymphat Disord; 2015 Apr; 3(2):135-41.e1. PubMed ID: 26993830
[TBL] [Abstract][Full Text] [Related]
30. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
[TBL] [Abstract][Full Text] [Related]
31. Use of proton pump inhibitors and risk of ischemic events in the general population.
Casula M; Scotti L; Galimberti F; Mozzanica F; Tragni E; Corrao G; Catapano AL
Atherosclerosis; 2018 Oct; 277():123-129. PubMed ID: 30212680
[TBL] [Abstract][Full Text] [Related]
32. Essen Risk Score in Prediction of Myocardial Infarction After Transient Ischemic Attack or Ischemic Stroke Without Prior Coronary Artery Disease.
Boulanger M; Li L; Lyons S; Lovett NG; Kubiak MM; Silver L; Touzé E; Rothwell PM
Stroke; 2019 Dec; 50(12):3393-3399. PubMed ID: 31637970
[TBL] [Abstract][Full Text] [Related]
33. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of prior ischemic stroke in patients with coronary artery disease undergoing percutaneous coronary intervention.
Wang H; Ning X; Zhu C; Yin D; Feng L; Xu B; Guan C; Dou K
Catheter Cardiovasc Interv; 2019 Feb; 93(S1):787-792. PubMed ID: 30618111
[TBL] [Abstract][Full Text] [Related]
35. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
36. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
[TBL] [Abstract][Full Text] [Related]
37. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
[TBL] [Abstract][Full Text] [Related]
38. Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults.
Ma Y; Li S; Yang H; Zhang Y; Li H; Zhou L; Lin J; Chen Y; Hou Y; Zhang X; Liu T; Zhou X; Wang Y
Atherosclerosis; 2022 Oct; 358():47-54. PubMed ID: 36113328
[TBL] [Abstract][Full Text] [Related]
39. PR interval prolongation in coronary patients or risk equivalent: excess risk of ischemic stroke and vascular pathophysiological insights.
Chan YH; Hai JJ; Lau KK; Li SW; Lau CP; Siu CW; Yiu KH; Tse HF
BMC Cardiovasc Disord; 2017 Aug; 17(1):233. PubMed ID: 28836952
[TBL] [Abstract][Full Text] [Related]
40. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; Goto S; Nilsen DW; Bonarjee V; Murphy SA; Morrow DA
J Am Coll Cardiol; 2014 Dec; 64(22):2318-26. PubMed ID: 25465417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
